The firm will use the funding to build a high-throughput flow cytometry system that sorts cells based on high-content 3D features.
The Boston-based company is working to make its extracellular vesicle detection technology more widely available for research and biomarker discovery.
The firm said CRISPR will enable targeted sequencing of long regions of interest that were previously only accessible with long-read whole-genome sequencing.
10x CEO and Cofounder Serge Saxonov reflected on how the firm's IPO got so big and how he plans to make the single-cell analysis firm even bigger.
The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.
The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.
The company believes that Xdrop will find adopters in academia and clinical research, although diagnostics is on its radar.
Spurred to develop new microfluidic chip technology, 10x told customers not to worry about the transition but told a court there would be "guaranteed hitches."
The SuperExtract 32 with the SuperExtract Viral Mag NA Purification kit provides high-quality purification of hepatitis and HIV viral nucleic acid.
The company provided updates on its newborn screening testing presence.
Researchers have launched a startup called Fluxus to commercialize a platform based on the optofluidic chip for molecular analysis.
In addition to the $24 million jury verdict, 10x must pay an additional $8.3 million in damages and $2.2 million in interest. It has appealed the case.
Researchers developed a microfluidic device that combines antibody-based cell capture and disulfide cleavage for downstream microRNA detection.
The firm will begin a verification study later this month using its cell-sorting platform and molecular analysis tool on patients with a pelvic mass scheduled for surgery.
The Methyl-HiC assay, which combines epigenetic and genome structure analyses, comes from a lab with a history of commercializing tests.
X Gen US, a California startup led by a veteran sequencing tools developer, says its kits can create single-cell RNA-seq libraries in less than two hours.
The exact restrictions the injunction will place on 10x are not yet determined. 10x will also have to pay Bio-Rad additional damages, plus interest.
Following a South Korean distribution agreement signed in May, the deal further expands the reach of NanoCellect's microfluidic-based cell handling products.
The researchers have applied for a patent on the method, dubbed MaPS-seq, which could be used to identify clinical biomarkers or turned into a kit.
Mirnax will use Arcis' nucleic acid sample preparation and preservation technology to improve the stability of miRNA biomarkers for early disease detection.
Nature News reports that gene therapy approaches are tackling sickle cell disease, but that the cost of treatment is a concern.
The Washington Post reports that a US Senate committee voted this week to approve the nomination of Stephen Hahn to lead the Food and Drug Administration.
One gene regulates hundreds of others to influence facial development, according to New Scientist.
In Nature this week: resources for single-cell analysis, little overlap in the microRNAs used by Salmonella and Shigella to infect host cells, and more.